LinkHealth Health Economics, Outcomes & Epidemiology s.r.l., Naples, Italy.
Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4490-4498. doi: 10.26355/eurrev_202107_26240.
To quantify the annual healthcare resource utilization, costs and mortality rate for a large cohort of Italian patients with compensated (CC) and decompensated cirrhosis (DC).
A population-based cohort study was conducted through the data-linkage of mortality for all-cause, hospitalizations and outpatient drugs and service databases of the Campania Region. All adults hospitalized with cirrhosis diagnosis (2007-2015) were grouped in CC and DC (prevalent patients) on January 1, 2016 and followed for 1-year. Incident patients with DC (2015) were also retrieved and followed from discharge date up to 1-year. Negative binomial regression was used to estimate Incidence Rate Ratios (IRRs) for predictors of all-cause hospitalizations. Costs were evaluated from the Italian National Health Service perspective and expressed in euro patient/year.
A total of 21,433 prevalent cirrhotic patients (57.1% CC and 42.9% DC) and 1,371 incident patients with DC were identified. During a 1-year, 21.5% of prevalent patients with CC were admitted for acute events, 26.8% of those with DC and 55.4% of incident patients with DC. Ascites (IRR=1.71;95% CI: 1.37-2.14) and hepatic encephalopathy (IRR=1.35; 95% CI: 1.04-1.77) at index admission were strong predictors of hospitalizations in incident DC patients. The 1-year mortality rate was respectively 5.8% and 10.1% for prevalent patients with CC and DC and 35.6% for incident patients with DC. Direct costs amounted to 3,194€ patient/year for the prevalent CC group and 4,001€ patient/year for the DC group and 13,806 € patient/year for incident individuals with DC.
The burden of cirrhosis dramatically differs between CC and DC patients, especially after the first decompensation episode. Ascites and hepatic encephalopathy at index admission were strong predictors of hospitalizations in incident DC patients.
量化意大利大量代偿性(CC)和失代偿性肝硬化(DC)患者的年度医疗资源利用、成本和死亡率。
通过对坎帕尼亚地区全因死亡率、住院和门诊药物及服务数据库进行数据链接,开展了一项基于人群的队列研究。2007 年至 2015 年期间,所有因肝硬化住院的成年人(2007-2015)于 2016 年 1 月 1 日被归入 CC 和 DC(现患患者)组,并随访 1 年。还从出院日期起检索并随访了 2015 年新发生的 DC 患者,随访至 1 年。采用负二项回归模型估计全因住院的预测因素的发病率比值(IRR)。从意大利国家卫生服务角度评估成本,并以欧元/患者/年表示。
共确定了 21433 例现患肝硬化患者(57.1%为 CC,42.9%为 DC)和 1371 例新发生的 DC 患者。在 1 年期间,21.5%的 CC 现患患者因急性事件住院,26.8%的 DC 现患患者和 55.4%的新发生的 DC 患者住院。入院时的腹水(IRR=1.71;95%CI:1.37-2.14)和肝性脑病(IRR=1.35;95%CI:1.04-1.77)是新发生的 DC 患者住院的强烈预测因素。CC 现患患者和 DC 现患患者的 1 年死亡率分别为 5.8%和 10.1%,新发生的 DC 患者的死亡率为 35.6%。CC 现患患者的直接成本为 3194 欧元/患者/年,DC 现患患者的直接成本为 4001 欧元/患者/年,新发生的 DC 患者的直接成本为 13806 欧元/患者/年。
CC 和 DC 患者的肝硬化负担差异很大,尤其是在首次失代偿后。入院时的腹水和肝性脑病是新发生的 DC 患者住院的强烈预测因素。